Trial Profile
A Phase 2 trial of EB-101 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB).
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 06 Sep 2016
Price :
$35
*
At a glance
- Drugs Prademagene zamikeracel (Primary)
- Indications Epidermolysis bullosa dystrophica
- Focus Therapeutic Use
- 06 Sep 2016 New trial record